Respiratory tract infection
RecruitingStudy on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19
Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19
- Disease:Respiratory tract infection
- Substances:Amoxicillin SodiumAzithromycin+17
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Amoxicillin Sodium
- Sponsor:Universitair Medisch Centrum Utrecht







